In this review, we summarize the latest advances in the management of SCLC and LCNEC, and discuss promising endeavors in development.doi:10.1016/j.ctarc.2020.100167Hussein A. AssiSukhmani K. PaddaCancer Treatment and Research Communications
Navigating treatment combinations in small-cell lung cancer The ETER701 trial demonstrates that a four-drug regimen, involving the addition of anti-angiogenesis therapy to immuno-chemotherapy, improves survival outcomes for extensive-stage small-cell lung cancer — but is more indeed better when it co...
HANSIZHUANG (serplulimab), Henlius’ first self-developed innovative Anti-PD-1 mAb, is the world’s first anti-PD-1 mAb for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Up to date, it has been approved in China and several Southeast Asian countries, benefiti...
Drug treatment which was once seen as only palliative is now considered to be potentially curative. Experts at the 9th International Congress on Anti -Cancer Treatment [ Paris, France; February 1999 ] reported various chemotherapy combinations under investigation for the treatment of this deadly ...
cells are rare immortal cells within a tumour that can both self-renew by dividing and give rise to many cell types that constitute the tumour, and can therefore form tumours. Such cells have been found in various types of human tumours and might be attractive targets for cancer treatment. ...
Find all the latest on lung cancer cells at Medical Xpress. Your go-to source for news, research, and medical breakthroughs.
in advanced NSCLC patients with MET overexpression. Together with the striking results in the pivotal study of SCC244 for the treatment of NSCLC withMETex14 skipping , which was presented at the AACR annual meeting 2022, SCC244 will become new treatment options for NSCLC patients in the future....
MedPacto will present clinical data from their combination therapy study of vactosertib for advanced non-small cell lung cancer (NSCLC). The phase 1b/2a trial results demonstrate synergistic effects when vactosertib is combined with durvalumab, with analysis focusing on treatment efficacy according ...
HANSIZHUANG (serplulimab), Henlius’ first self-developed innovative Anti-PD-1 mAb, is the world’s first anti-PD-1 mAb for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Up to date, it has been approved in China and several Southeast Asian countries. Underpin...
Relapsed small cell lung cancer: Treatment options and latest developments According to recent analyses, there was a modest yet significant improvement in median survival time and 5-year survival rate of limited stage small cell l... N Asai,Y Ohkuni,N Kaneko,... - 《Therapeutic Advances in ...